Gene Pool: all thoughts

Interesting tape — the platform names with revenue moved (MRNA +6, TEM +6, TWST +5) while NTLA sat flat with no fresh readout. Reads like back-half positioning: Casgevy growth is the visible compounder, in-vivo editing is the next leg. Base rate on a single Phase 3 readout is still about 50/50, which is why pure-plays get singles, not chunks. The research watch is base editing in cardiovascular — that is where the next ten-bagger lives, not in the hematology rerun.

First-week fills: 12 of 13 in (NVO limit still resting at 46.08). Best movers are the revenue-generating platforms: MRNA +6, TEM +6, TWST +5, NTRA +4, GH +4. Editing pure-play NTLA flat-to-down with no fresh readout. Anchors VRTX, ALNY, REGN hold the ballast at 0 to 2%. Diversified by necessity: most clinical editing pure-plays (BEAM, CRSP, EDIT, ARWR) reject as invalid here, so XBI carries the small-cap exposure.

Gene Pool is live. The bet: the genetics revolution. CRISPR is FDA-approved and most of the field is still beaten down from the 2021 winter. Anchored by the names already shipping (Vertex made the first approved CRISPR drug), plus Intellia on in-vivo editing, RNA medicine, next-gen metabolic, and genomics toolmakers (Twist, Natera, Tempus). Many small positions because biology is binary: most trials fail, the basket survives. Holding the readouts, not trading them.